STING1 and cancer: To overcome the problems of Gd‐based contrast agents (GBCAs) (nephrotoxicity and brain deposition) and stimulator of interferon genes (STING) agonists (poor stability, low delivery efficiency, and potential toxicity), in this study, a Turbo‐charging system‐like GBCA is designed and constructed for magnetic resonance imaging (MRI) guided STING pathway‐activated cancer immunotherapy.